ID: ALA2048237

Max Phase: Preclinical

Molecular Formula: C13H15NO6P2

Molecular Weight: 343.21

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=P(O)(O)C(Cc1cncc(-c2ccccc2)c1)P(=O)(O)O

Standard InChI:  InChI=1S/C13H15NO6P2/c15-21(16,17)13(22(18,19)20)7-10-6-12(9-14-8-10)11-4-2-1-3-5-11/h1-6,8-9,13H,7H2,(H2,15,16,17)(H2,18,19,20)

Standard InChI Key:  ZJOQFOORZUSDPB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 343.21

Molecular Weight (Monoisotopic): 343.0375

AlogP: 1.97

#Rotatable Bonds: 5

Polar Surface Area: 127.95

Molecular Species: ACID

HBA: 3

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.20

CX Basic pKa: 4.54

CX LogP: -1.98

CX LogD: -4.74

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.61

Np Likeness Score: -0.31

References

1. Lin YS, Park J, De Schutter JW, Huang XF, Berghuis AM, Sebag M, Tsantrizos YS..  (2012)  Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.,  55  (7): [PMID:22390415] [10.1021/jm201657x]

2. De Schutter JW, Shaw J, Lin YS, Tsantrizos YS..  (2012)  Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.,  20  (18): [PMID:22884353] [10.1016/j.bmc.2012.07.019]

Source

Source(1):

• Scientific Literature